Trishna Goswami
Technik-/Wissenschafts-/F&E-Leiter bei IN8BIO, INC.
Vermögen: 8 008 $ am 31.05.2024
Profil
Dr. Trishna Goswami is a Chief Medical Officer at IN8bio, Inc. Dr. Goswami was previously employed as a Vice President-Clinical Development by Immunomedics, Inc., a Senior Director-Medical by Stemline Therapeutics, Inc., and a Vice President-Clinical Development by Gilead Sciences, Inc. She received her MBA from Robert H.
Smith School of Business and a doctorate degree from Drexel University College of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IN8BIO, INC.
0,02% | 17.04.2024 | 6 729 ( 0,02% ) | 8 008 $ | 31.05.2024 |
Aktive Positionen von Trishna Goswami
| Unternehmen | Position | Beginn |
|---|---|---|
| IN8BIO, INC. | Technik-/Wissenschafts-/F&E-Leiter | 16.11.2021 |
Ehemalige bekannte Positionen von Trishna Goswami
| Unternehmen | Position | Ende |
|---|---|---|
| IMMUNOMEDICS, INC. | Corporate Officer/Principal | 01.12.2021 |
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.06.2018 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
Ausbildung von Trishna Goswami
| Drexel University College of Medicine | Doctorate Degree |
| Robert H. Smith School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| IN8BIO, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
